Ecopia BioSciences Inc.

Ecopia BioSciences Inc.

June 06, 2006 08:30 ET

Ecopia Presents at the Natural Products Discovery and Production Symposium in New Mexico

MONTREAL, QUEBEC--(CCNMatthews - June 6, 2006) - (TSX:EIA) Dr Jim McAlpine, Vice-President, Chemistry and Discovery, today made a presentation about the ability of the DECIPHER® platform to discover New Chemical Entities (NCE) from bacteria. The DECIPHER® technology is Ecopia's unique drug discovery platform from which more than 59 NCEs were discovered including ECO-4601; the company's lead anticancer product now in Phase I clinical trial.

The presentation, entitled "In Silico Biosynthesis: A Potent New Approach To Natural Product Discovery", was made during the Natural Products Discovery and Production Symposium held in Santa Fe, New Mexico.

Ecopia's DECIPHER® platform represents a new paradigm in the discovery of natural products by applying bioinformatics and genomic tools to one of the most abundant sources of successful drugs known in modern medical history. The source is soil-dwelling microorganisms that have produced several potent anticancer agents such as doxorubicin, bleomycin and mitomycin.

About Ecopia

Ecopia is finding novel anticancer therapies from soil-dwelling microorganisms that are one of the most prolific sources of drugs. Our current focus is to advance our flagship compound, ECO-4601, through the different stages of Phase I clinical trial. ECO-4601 is a novel small molecule that crosses the blood brain barrier and is effective in significantly inhibiting primary brain tumor growth and other types of cancers. Just like well-known chemotherapies such as doxorubicin and mitomycin C, ECO-4601 comes from microorganisms that live in common soil. However, unlike these drugs that were discovered many decades ago, ECO-4601 represents a new chemical class that is the fruit of a very unique drug discovery platform called the DECIPHER® technology. The common shares of Ecopia are listed on the TSX (symbol: EIA).

This press release may contain forward-looking statements that reflect the Company's current expectations regarding future events. The forward-looking statements, including expectations as to the advancement of ECO-4601 through the different stages of Phase I clinical trial, the novelty of ECO-4601 and the pharmaceutical potential of ECO-4601 to inhibit primary brain tumor growth and other types of cancers involve risk and uncertainties. Actual events could differ materially from those projected here and depend on a number of factors, including timely progress and completion of the on-going Phase I clinical study, differences in novelty assessment by various patent offices, scientific uncertainties relating to the correlation between demonstrated efficacy of ECO-4601 in preclinical animal models and expected clinical efficacy in humans, and the impact of general economic conditions. Investors are cautioned against placing undue reliance on forward-looking statements. A more complete discussion of the risks and uncertainties facing the Company appears in Ecopia's 2005 Annual Report.

Contact Information